Pepticom’s unique artificial intelligence (AI) technology streamlines and significantly accelerates the ability of researchers to discover advanced peptide-based drug candidates. Peptides are used in various therapies, and are recognized for being highly selective and efficacious as well as relatively safe. The pharma industry has recently shown an increased interest in peptide research and development, leading to a resurgence of peptide drug candidates. The process of discovering new peptides with lifesaving potential, however, is still costly and time consuming. Pepticom’s AI technology enables the discovery of the most advanced peptide-based drug candidates by searching an enormous set of possible solutions, vastly reducing the risk of failure during development.
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
Categories
Follow Us
Tags
AI
Alzheimer
antibodies
Azitra
Bioeq
Biosimilar
Cancer
cardiovascular
cell therapy
CE Mark
clinical trial
Diagnostics
Digital Health
Distribution
Drug Discovery
Enterome
EpiVax'
FDA
FDA approval
funding
fundraising
HIV
Immunogenicity
Immunotherapies
Licensing
M&A
medical device
microbiome
Neuro
next-gen sequencing
PathAI
pathology
Pepticom
pharma
RNA
robots
Shape Therapeutics
skin
software
SurgiMab
Therapeutics
therapies
USA
VIrology
Virus